Celgene Corporation (CELG) Rating Reiterated by Mizuho

Celgene Corporation (NASDAQ:CELG)‘s stock had its “buy” rating reiterated by analysts at Mizuho in a research note issued to investors on Friday, November 3rd.

Several other analysts also recently issued reports on CELG. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $166.00 price objective (up previously from $163.00) on shares of Celgene Corporation in a research report on Monday, October 30th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $112.00 price objective on shares of Celgene Corporation in a research report on Monday, October 30th. J P Morgan Chase & Co set a $123.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Friday, October 27th. UBS AG lowered their price objective on shares of Celgene Corporation from $146.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, October 27th. Finally, Canaccord Genuity reissued a “buy” rating and set a $140.00 price target (down previously from $154.00) on shares of Celgene Corporation in a research report on Friday, October 27th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $139.57.

Celgene Corporation (NASDAQ:CELG) traded up $0.66 during trading hours on Friday, hitting $105.16. 4,069,084 shares of the stock were exchanged, compared to its average volume of 4,736,209. The firm has a market cap of $82,790.00, a PE ratio of 16.12, a PEG ratio of 0.80 and a beta of 1.79. Celgene Corporation has a fifty-two week low of $94.55 and a fifty-two week high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.

Celgene Corporation (NASDAQ:CELG) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.58 EPS. analysts forecast that Celgene Corporation will post 6.67 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was first published by BBNS and is the property of of BBNS. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://baseballnewssource.com/markets/celgene-corporation-celg-earns-buy-rating-from-mizuho/1755056.html.

In other Celgene Corporation news, insider Terrie Curran sold 1,727 shares of the stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the sale, the director now owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The disclosure for this sale can be found here. Insiders sold 20,227 shares of company stock worth $2,843,956 in the last three months. Insiders own 0.95% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. Capital Counsel LLC NY grew its holdings in shares of Celgene Corporation by 0.4% during the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock worth $214,000 after buying an additional 6 shares in the last quarter. Fort Pitt Capital Group LLC grew its holdings in shares of Celgene Corporation by 0.6% during the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 11 shares in the last quarter. Sowell Financial Services LLC grew its holdings in shares of Celgene Corporation by 0.5% during the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 13 shares in the last quarter. South Texas Money Management Ltd. grew its holdings in shares of Celgene Corporation by 0.6% during the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 15 shares in the last quarter. Finally, Flagship Harbor Advisors LLC boosted its position in Celgene Corporation by 0.9% during the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after purchasing an additional 18 shares during the last quarter. Institutional investors and hedge funds own 79.48% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.